NewAmsterdam Pharma Price to Free Cash Flow Ratio 2021-2024 | NAMS

NewAmsterdam Pharma price to free cash flow ratio from 2021 to 2024. Price to free cash flow ratio can be defined as

NewAmsterdam Pharma Price to Free Cash Flow Ratio 2021-2024 | NAMS

NewAmsterdam Pharma price to free cash flow ratio from 2021 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$76.8B
Chugai Pharmaceutical (CHGCY)$66.9B
Takeda Pharmaceutical (TAK)$42.4B
Sandoz Group AG (SDZNY)$20.6B
Merck (MKKGY)$20B
Astellas Pharma (ALPMY)$17.7B
United Therapeutics (UTHR)$16.6B
Summit Therapeutics (SMMT)$16B
Neurocrine Biosciences (NBIX)$15.3B
Shionogi (SGIOY)$12.5B
Orion OYJ (ORINY)$7.5B
Madrigal Pharmaceuticals (MDGL)$7.1B
Stevanato Group S.p.A (STVN)$6.5B
Corcept Therapeutics (CORT)$6.4B
Hikma Pharmaceuticals Plc (HKMPF)$5.9B
Ionis Pharmaceuticals (IONS)$5.2B
Ono Pharmaceutical (OPHLF)$4.9B
Grifols, S.A (GRFS)$4.8B
Crinetics Pharmaceuticals (CRNX)$3.7B
Catalyst Pharmaceuticals (CPRX)$2.9B
Recursion Pharmaceuticals (RXRX)$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Centessa Pharmaceuticals (CNTA)$2.2B
Soleno Therapeutics (SLNO)$2.1B
Hypermarcas (HYPMY)$1.9B
Indivior (INDV)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.7B
Evotec AG (EVO)$1.5B
Guardian Pharmacy Services (GRDN)$1.4B
ARS Pharmaceuticals (SPRY)$1.4B